JP2018511634A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511634A5
JP2018511634A5 JP2017553956A JP2017553956A JP2018511634A5 JP 2018511634 A5 JP2018511634 A5 JP 2018511634A5 JP 2017553956 A JP2017553956 A JP 2017553956A JP 2017553956 A JP2017553956 A JP 2017553956A JP 2018511634 A5 JP2018511634 A5 JP 2018511634A5
Authority
JP
Japan
Prior art keywords
crystalline form
cancer
dihydro
solvent
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017553956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511634A (ja
JP7320741B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/079251 external-priority patent/WO2016165626A1/en
Publication of JP2018511634A publication Critical patent/JP2018511634A/ja
Publication of JP2018511634A5 publication Critical patent/JP2018511634A5/ja
Priority to JP2021009106A priority Critical patent/JP7383652B2/ja
Application granted granted Critical
Publication of JP7320741B2 publication Critical patent/JP7320741B2/ja
Priority to JP2023190552A priority patent/JP2024012540A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017553956A 2015-04-15 2016-04-14 B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 Active JP7320741B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021009106A JP7383652B2 (ja) 2015-04-15 2021-01-22 B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP2023190552A JP2024012540A (ja) 2015-04-15 2023-11-08 B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/076639 2015-04-15
CN2015076639 2015-04-15
PCT/CN2016/079251 WO2016165626A1 (en) 2015-04-15 2016-04-14 Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021009106A Division JP7383652B2 (ja) 2015-04-15 2021-01-22 B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Publications (3)

Publication Number Publication Date
JP2018511634A JP2018511634A (ja) 2018-04-26
JP2018511634A5 true JP2018511634A5 (https=) 2019-05-23
JP7320741B2 JP7320741B2 (ja) 2023-08-04

Family

ID=57125563

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017553956A Active JP7320741B2 (ja) 2015-04-15 2016-04-14 B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP2021009106A Active JP7383652B2 (ja) 2015-04-15 2021-01-22 B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP2023190552A Withdrawn JP2024012540A (ja) 2015-04-15 2023-11-08 B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021009106A Active JP7383652B2 (ja) 2015-04-15 2021-01-22 B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP2023190552A Withdrawn JP2024012540A (ja) 2015-04-15 2023-11-08 B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Country Status (15)

Country Link
US (1) US10351559B2 (https=)
EP (2) EP3283486B1 (https=)
JP (3) JP7320741B2 (https=)
KR (2) KR102643609B1 (https=)
CN (2) CN113307805A (https=)
AU (1) AU2016248376B2 (https=)
CA (1) CA2981746C (https=)
EA (1) EA035680B1 (https=)
IL (2) IL287740B2 (https=)
MX (1) MX381053B (https=)
NZ (1) NZ735715A (https=)
SG (1) SG11201707984TA (https=)
TW (4) TWI792406B (https=)
WO (1) WO2016165626A1 (https=)
ZA (1) ZA201706392B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
US9273046B2 (en) 2011-12-31 2016-03-01 Beigene, Ltd. Fused tricyclic compounds as Raf kinase inhibitors
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
NZ735715A (en) * 2015-04-15 2022-09-30 Beigene Ltd Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス, インコーポレイテッド 炎症性障害の処置
WO2020033344A1 (en) * 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
HUE062000T2 (hu) * 2018-10-31 2023-09-28 Servier Lab BCL-2 inhibitor új sója, vonatkozó kristályforma, ezek elõállítási eljárása és ezeket tartalmazó gyógyszerkészítmények
CN111484488A (zh) * 2019-01-25 2020-08-04 百济神州(北京)生物科技有限公司 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
CN111484489B (zh) * 2019-01-25 2023-05-23 百济神州(北京)生物科技有限公司 无定形的b-raf激酶二聚体抑制剂
EP3937936A4 (en) * 2019-03-15 2022-12-28 Forma Therapeutics, Inc. INHIBITION OF CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB)
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN111184693B (zh) * 2019-05-29 2023-07-21 百济神州(苏州)生物科技有限公司 一种raf激酶抑制剂制剂及其制备方法
US20230128315A1 (en) * 2020-04-03 2023-04-27 Beigene, Ltd. Co-administration of mirdametinib and lifirafenib for use in treating cancers
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
WO2023240178A1 (en) * 2022-06-08 2023-12-14 Mapkure, Llc Methods of treating cancer with a b-raf inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005316668B2 (en) 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CN101365682A (zh) 2005-12-08 2009-02-11 千禧药品公司 具有激酶抑制活性的双环化合物
ATE552245T1 (de) 2006-05-15 2012-04-15 Merck Sharp & Dohme Antidiabetische bicyclische verbindungen
US20100292205A1 (en) 2006-08-23 2010-11-18 Pfizer Inc. Pyrimidone Compounds As GSK-3 Inhibitors
EP2061761A1 (en) 2006-09-07 2009-05-27 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
EA016329B1 (ru) 2007-05-04 2012-04-30 Айрм Ллк СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
US20100197924A1 (en) 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
CN103476770B (zh) * 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
US9273046B2 (en) * 2011-12-31 2016-03-01 Beigene, Ltd. Fused tricyclic compounds as Raf kinase inhibitors
NZ735715A (en) 2015-04-15 2022-09-30 Beigene Ltd Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore

Similar Documents

Publication Publication Date Title
JP2018511634A5 (https=)
JP2018528199A5 (https=)
JP2020033359A5 (https=)
AU2016260279B2 (en) Crystals of azabicyclic compound
TWI826373B (zh) (s)-2-((2-((s)-4-(二氟甲基)-2-氧代唑烷-3-基)-5,6-二氫苯并[f]咪唑并[1,2-d][1,4]氧氮呯-9-基)胺基)丙醯胺之多晶型及固體形式及製造方法
JP2013518041A5 (https=)
CN107531682A (zh) B‑raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途
JP2019515024A (ja) ボルチオキセチンのパモ酸塩及びその結晶形
JP2020517611A5 (https=)
CA3142088A1 (en) Compound used as kinase inhibitor and application thereof
CA3009713A1 (en) Crystalline forms of ponesimod and preparation method thereof
JP7124035B2 (ja) アクリジニウム臭化物の製造方法
CA3083022A1 (en) Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
JP2013541589A5 (https=)
JP6676626B2 (ja) アシルチオウレア化合物のメシル酸塩の結晶及びその製造方法
ES2727667T3 (es) Polimorfos de lenalidomida
JP2020530497A (ja) 3−(5−フルオロベンゾフラン−3−イル)−4−(5−メチル−5H−[1,3]ジオキソロ[4,5−f]インドール−7−イル)ピロール−2,5−ジオンの固体形態
CN111315748B (zh) 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮晶体
JP2015521635A5 (https=)
JP6165335B2 (ja) ゲフィチニブの新規な結晶形およびその製造方法
WO2018214877A1 (zh) 一种地佐辛晶型及其制备方法
JPWO2011152411A1 (ja) チエノピリミジン誘導体の結晶
JP2010229098A (ja) イソインドリン誘導体のa型の結晶形の製造方法及びイソインドリン誘導体のa型の結晶形
JP7340534B2 (ja) トレプロスチニルジエタノールアミン塩の多形形態bを製造するための方法